Fulcrum Therapeutics announced the appointment of Alan Musso as CFO, effective August 7. A 30-year veteran in the life sciences industry, Musso has held numerous financial and operational leadership positions over the course of his career. Prior to joining Fulcrum, Alan served for several years as CFO of ReViral, which was acquired by Pfizer in 2022.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on FULC:
- Fulcrum Therapeutics expects cash to fund operations into mid-2025
- Fulcrum Therapeutics reports Q2 EPS (38c), consensus (44c)
- Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for Second Quarter 2023
- Fulcrum Therapeutics Appoints Chief Financial Officer
- Fulcrum Therapeutics Signs Exclusive Global License Agreement in Rare Hematology